Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous...
Brand Name : Catiolanze
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Brand Name : Flarex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Brand Name : Flarex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tafluprost,Timolol Maleate
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Brand Name : STN1011101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 08, 2023
Lead Product(s) : Tafluprost,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Glycerine,Tyloxapol API,Detalan
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...
Brand Name : Cationorm Plus
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2022
Lead Product(s) : Glycerine,Tyloxapol API,Detalan
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : UBE Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension...
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2022
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : UBE Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Brand Name : Verkazia
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 02, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Alcon Inc
Deal Size : $168.0 million
Deal Type : Expanded Collaboration
Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...
Brand Name : Rhopressa
Molecule Type : Small molecule
Upfront Cash : $88.0 million
December 07, 2021
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Alcon Inc
Deal Size : $168.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Sydnexis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help co...
Brand Name : SYD-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Sydnexis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?